Clinical Progress and Preclinical Insights Into Umbilical Cord Blood Transplantation Improvement

Zhongjie Sun1,3, Bing Yao4, Huangfan Xie2,3,*, XunCheng Su1,*,

1State Key Laboratory of Elemento-organic chemistry, College of Chemistry, Nankai University, Tianjin, People's Republic of China
2School of Pharmaceutical Sciences, Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology (Ministry of Education), Tsinghua University, Beijing, People’s Republic of China
3Newish Technology (Beijing) Co., Ltd., Beijing, People’s Republic of China

*Corresponding author: XunCheng Su, PhD, College of Chemistry, Nankai University, Tianjin 300071, People’s Republic of China. Tel: +86 0222 3503067; Fax: +86 0222 3503067; Email: xunchengsu@nankai.edu.cn; or, Huangfan Xie, PhD, School of Pharmaceutical Sciences, Tsinghua University, Beijing 100084, People’s Republic of China. Tel: +86 18911953404; Email: xiehuangfan@126.com

Abstract

The application of umbilical cord blood (UCB) as an important source of hematopoietic stem and progenitor cells (HSPCs) for hematopoietic reconstitution in the clinical context has steadily grown worldwide in the past 30 years. UCB has advantages that include rapid availability of donors, less strict HLA-matching demands, and low rates of graft-versus-host disease (GVHD) versus bone marrow (BM) and mobilized peripheral blood (PB). However, the limited number of HSPCs within a single UCB unit often leads to delayed hematopoietic engraftment, increased risk of transplant-related infection and mortality, and proneness to graft failure, thus hindering wide clinical application. Many strategies have been developed to improve UCB engraftment, most of which are based on 2 approaches: increasing the HSPC number ex vivo before transplantation and enhancing HSPC homing to the recipient BM niche after transplantation. Recently, several methods have shown promising progress in UCB engraftment improvement. Here, we review the current situations of UCB manipulation in preclinical and clinical settings and discuss challenges and future directions.

Key words: umbilical cord blood; hematopoietic stem and progenitor cells; engraftment; ex vivo expansion; homing; clinical trial.

Graphical Abstract
Significance Statement
Many strategies have been developed to improve UCB engraftment, most of which are based on 2 approaches: increasing the HSPC number ex vivo before transplantation and enhancing HSPC homing to the recipient BM niche after transplantation. Recently, several methods have shown promising progress in UCB engraftment improvement. This article summarizes clinical trials on UCB transplantation improvement from the earliest to the latest publications, covering ex vivo expansion and promotion of homing. The latest preclinical studies on UCB engraftment improvement by various approaches are also discussed, which are not available in other recently published reviews.

Introduction
Hematopoietic stem cells (HSCs) are a type of adult stem cell that can provide a steady lifelong pool of various hematopoietic and immune cells. HSC transplantation (HSCT) has been applied clinically to treat more than 80 diseases, including hematological malignancies and disorders. There are approximately 70,000 cases of HSCT worldwide annually. The most commonly used HSC sources are mobilized peripheral blood (PB) and to a lesser extent bone marrow (BM). Alternatively, wide application of PB- and BM-based HSCT has been hindered by the strict demand for HLA matching and severe GVHD. Umbilical cord blood (UCB), with less stringent HLA-matching demand, ready availability, and lower risk of graft-versus-host disease (GVHD), has become an alternative source for HSCT.

UCB HSCT has been developed for 30 years, and it is estimated that the total number of UCB HSCT cases worldwide exceeds 45,000, and the number of cases of UCB HSCT is still growing. Overall, approximately 800,000 and 4,000,000 UCB units have been stored in public and private banks, respectively. However, limitations of UCB HSCT are that a relatively low number of HSPCs in a single UCB unit cannot meet the demand for adult HSCT and that hematopoietic and immune recovery after UCB HSCT is delayed, resulting in a high risk of infection and mortality; in addition, UCB HSCT is more prone to graft failure than BM or mobilized PB transplantation.

Clinical Trials on UCB Engraftment Improvement
Clinical trials on UCB engraftment improvement are usually based on preclinical studies showing benefits for engraftment after certain manipulations. As HSC markers have yet to be defined, these studies have regarded CD34+ cells or CD133+ cells, a heterogeneous population containing long-term repopulating HSCs, as putative HSCs. Therefore, functional assessment of these cells after manipulation is of great importance. In preclinical studies, limiting dilution assay (LDA) in transplantation models is used to count the number of HSCs among input cells, whereby long-term HSCs are able to reconstitute in irradiated immunodeficient recipient NOD/SCID mice (or subsequent adaptations of this mouse strain, for instance, NSG and NOG mice) for more than 24 weeks, with both lymphoid and myeloid repopulation. In general, UCB engraftment kinetics in patient recipients are slow in the absence of manipulation. The median time to neutrophil and platelet recovery after double UCB transplantation (UCBT) is approximately 27 and 48 days, respectively, twice that of BM and mobilized PB HSCT. Therefore, the most important aim of UCB manipulation is to shorten the median time to engraftment. Tables 1 and 2 summarize clinical trials on UCBT improvement.

Expansion of UCB
Cytokine-based Expansion
Early work that aimed at enhancing UCB engraftment focused on the cytokines that promote HSPC survival and self-renewal. In these settings, UCB was cultured ex vivo in growth medium containing a combination of cytokines, often including stem cell factor (SCF), thrombopoietin (TPO), FMS-related tyrosine kinase 3 ligand (FL), interleukin-3 (IL-3), interleukin-6 (IL-6), granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF), to allow for proliferation of HSCs. The challenge with this strategy is that it is difficult to control the concentration and time-window of individual cytokines in real-time; as a result, differentiation was promoted, and transplantable HSCs did not increase in number. In a clinical trial in which UCB was expanded for 10 days with a combination of SCF, G-CSF and megakaryocyte growth and development factor (MGDF), 56.0- and 4.0-fold increases in total cell and CD34+ cell numbers, respectively, were achieved. However, there was no improvement in neutrophil and platelet recovery. Besides, higher rates of acute (66.7%) and chronic (74.0%) GVHD were observed in the patients than those of contemporary studies, reflecting a change in HSPC biology after expansion.

Copper Chelator-mediated Expansion
One clinical trial was based on the observation that supplementation with tetraethylenepentamine (TEPA), a copper chelator, reduced differentiation and increased engraftment of UCB CD34+ cells in NOD/SCID mice. In this trial, UCB was split into 2 portions, one in which CD133+ cells were selected and subsequently expanded with growth medium containing TEPA, SCF, FL, IL-6, TPO for 21 days; the other portion was not manipulated. With this regimen, patients received an unmanipulated portion and subsequently expanded portions. The fold expansion of CD34+ cells was 6.0,
and the median time to neutrophil and platelet recovery was 30 and 48 days, respectively. Since this trial, 2 other phase II/III trials (NCT00469729 and NCT01484470) have been completed in multiple centers. For 101 patients who received TEPA-expanded UCB units, faster median neutrophil (21 days vs 28 days) and platelet (54 days vs 105 days) recovery was achieved compared with 295 patients receiving unmanipulated double UCB units (NCT00469729). There was also an advantage in 100-day survival for TEPA group compared with unmanipulated group (84.2% vs 74.6%). In this case, acute and chronic GVHD rates were similar between both groups. Notably, in this trial, an amazing 77.0-fold increase in CD34+ number was reported for a 21-day culture, but the cause for the difference from the previous phase I trial (6.0-fold increase) was not clear.

**Notch-mediated Expansion**

Activation of Notch signaling via surface Notch receptors promotes HSC self-renewal. In a preclinical study, it was found that among various Notch ligands, an immobilized form of DLL1 (DLL1ext-lgG) performed best at UCB HSC expansion. A clinical trial in which UCB units were cultivated with DLL1ext-lgG for 16 days reported a 164.0-fold increase in CD34+ cell number. After receiving one unmanipulated and one DLL1ext-lgG-expanded UCB unit, patients showed a markedly shortened median time to engraftment (16 days). Rapid myeloid recovery in recipients of DLL1ext-lgG-expanded UCB units also occurred in the early period, at 7 days post-UCBT. Nevertheless, only one of 10 patients exhibited an expanded cell population in the engraftment at 1 year posttransplantation, indicating a lack of long-term HSCs after DLL1ext-lgG-mediated expansion. In addition, all patients experienced grade II GVHD, a significantly higher rates than those of conventional studies.

**Nicotinamide-mediated Expansion**

Nicotinamide is a precursor to nicotinamide adenine dinucleotide (NAD) and inhibits SIRT1 activity, and addition of nicotinamide prevents UCB CD34+ cells from differentiating. A clinical product, NiCord, has been developed and applied in phase I and II trials. A pilot study with 11 participants found that the median time to neutrophil and platelet recovery was shortened to 13 and 33 days, respectively, when using NiCord and unmanipulated UCB units. Only 5 patients experienced grade II GVHD in this trial. Moreover, one patient had mixed chimerism at 3 years posttransplantation, suggesting the existence of long-term HSCs in the Nicord portion. Based on this observation, another trial evaluated the effect of a single NiCord infusion on UCBT. Among 36 participants, 34 showed engraftment, and the median time to neutrophil and platelet recovery was markedly shortened (11.5 and 34 days, respectively). Importantly, lower rates of acute (44% versus 56%) GVHD were observed in patients with NiCord infusion than those in comparator cohort.
### Table 1. List of clinical trials on UCB manipulation.

| Manipulation | Strategy | Conditions                     | ClinicalTrials.gov identifier | Status                   | Locations                                                                                           |
|--------------|----------|--------------------------------|-------------------------------|--------------------------|-----------------------------------------------------------------------------------------------------|
| Expansion    |          |                                |                               |                          |                                                                                                     |
| Cytokines    | Single UCB: one portion with CD34+ cells selected and expanded; the other unmanipulated | Hematologic malignancies      | NA                           | NA; Completed             | University of Colorado, Denver, Colorado, US                                                       |
| UM171        | Single UCB with CD34+ cells selected and expanded; CD34- cells are also infused | Hematologic malignancies      | NCT02668315                  | Phase I/II; Completed       | Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada                                             |
| UM171        | Single UCB with CD34+ cells selected and expanded; CD34- cells are also infused | High-risk hematological malignancies | NCT04103879                  | Phase II; Recruiting        | Fred Hutchinson/University of Washington Cancer Consortium, Seattle, Washington, US                |
| UM171        | Single UCB with CD34+ cells selected and expanded; CD34- cells are also infused | Multiple myeloma              | NCT03441958                  | Phase I/II; Recruiting       | CIUSSS de l’Est-de-l’île-de-Montréal, Installation Hôpital Maisonneuve Rosemond, Montréal, Quebec, Canada |
| UM171        | Single UCB with CD34+ cells selected and expanded; CD34- cells are also infused | High-risk hematological malignancies | NCT03913026                  | Phase II; Recruiting        | CIUSSS de l’Est-de-l’île-de-Montréal, Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada       |
| UM171        | Single UCB with CD34+ cells selected and expanded; CD34- cells are also infused | High-risk myeloid malignancies | NCT04990323                  | Phase I/II; Recruiting       | Memorial Sloan Kettering Cancer Center, New York, New York, US                                      |
| UM171        | Single UCB with CD34+ cells selected and expanded; CD34- cells are also infused | Sickle cell disease           | NCT04594031                  | Phase I; Recruiting         | Stanford University School of Medicine, Palo Alto, California, US; University of California San Francisco, San Francisco, California, US |
| SR-1         | Double UCB; one with CD34+ cells selected and expanded; CD34- cells are also infused; the other unmanipulated | Hematologic malignancies      | NCT01474681                  | Phase I/II; Completed        | Novartis Investigative Site, Minneapolis, Minnesota, US                                             |
| SR-1         | Double UCB; one with CD34+ cells selected and expanded; CD34- cells are also infused; the other unmanipulated | Inherited metabolic disorders | NCT03406962                  | Phase II; Completed         | University of Minnesota, Minneapolis, Minnesota, US; Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, US |
| Nicotinamide | Double UCB; one with AC133+ cells selected and expanded; AC133- cells are also infused; the other unmanipulated | Hematological malignancies    | NCT01221857                  | Phase I/II; Completed        | Loyola University, Cardinal Bernardin Cancer Center, Maywood, Illinois, US; Duke University Medical Center, Durham, North Carolina, US |
| Nicotinamide | Single UCB with AC133+ cells selected and expanded; AC133- cells are also infused; the other unmanipulated | Hematological malignancies    | NCT01816230                  | Phase I/II; Completed        | Multicenter in US, Italy, Netherlands, Singapore and Spain                                          |
| TEPA         | Single UCB with expanded and unmanipulated portions | Hematologic malignancies      | NCT00469729                  | Phase II/III; Completed     | Multicenter in US, Hungary, Israel, Italy and Spain                                                  |
| TEPA         | Single UCB with expanded and unmanipulated portions | Hematologic malignancies      | NCT01484470                  | Phase II; Completed         | Loyola University Medical Center, Maywood, Illinois, US                                               |
| Valproic Acid| Double UCB; one with CD34+ cells selected and expanded; CD34- cells are also infused; the other is unmanipulated | Hematologic malignancies      | NCT03885947                  | Phase I; Completed           | Icahn School of Medicine at Mount Sinai, New York, New York, US                                      |
| Manipulation | Strategy | Conditions | ClinicalTrials.gov identifier | Status | Locations |
|-------------|----------|------------|-------------------------------|--------|-----------|
| Delta1ext-IgG | Double UCB; one with CD34+ cells selected and expanded; the other is unmanipulated | Hematologic malignancies | NA | Phase I; Completed | Fred Hutchinson Cancer Research Center, Seattle, Washington, US |
| MSC | Double UCB; one expanded on MSC, the other is unmanipulated | Myelodysplastic syndrome; Leukemia | NCT00498316 | Phase I; Completed | University of Texas MD Anderson Cancer Center, Houston, Texas, US |
| MSC | Double UCB; one expanded on MSC, the other is unmanipulated | Hematological malignancies | NCT01624701 | Phase I/II; Terminated (Funding expired) | Singapore General Hospital, Singapore |
| Homing | Double UCB; one primed with C3a, the other is unmanipulated | Hematological malignancies | NCT00963872 | Phase I/II; Terminated (Lack of efficacy after interim analysis) | University of Minnesota Medical Center—Fairview, Minneapolis, Minnesota, US |
| Sitagliptin | Single UCB with sitagliptin taken orally | Hematological malignancies | NCT00862719 | Phase II; Completed | Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, US; New York Medical College/Westchester Medical Center/Maria Fareri Children's Hospital, Valhalla, New York, US |
| Sitagliptin | Single UCB with sitagliptin taken orally | Hematological malignancies | NCT01720264 | Phase II; Completed | IU Simon Cancer Center, Indianapolis, Indiana, US; New York Medical College/Westchester Medical Center/Maria Fareri Children's Hospital, Valhalla, New York, US |
| PGE2 | Single FT1050-treated UCB unit | Hematological malignancies | NCT01527838 | Phase I; Completed | Massachusetts General Hospital, Boston, Massachusetts, US; Dana Farber Cancer Institute-Hematopoietic Stem Cell Transplant Program, Boston, Massachusetts, US; Ohio State University Comprehensive Cancer Center, Columbus, Ohio, US |
| PGE2 | Single FT1050-treated UCB unit | Metabolic disorders | NCT02354443 | Phase I; Terminated (Business decision) | Boston Children's Hospital, Boston, Massachusetts, US; Duke University Medical Center, Durham, North Carolina, US |
| PGE2 | Single FT1050-treated UCB unit | Hematologic malignancies | NCT02354417 | Phase I; Terminated | City of Hope, Duarte, California, US; Boston Children's Hospital, Boston, Massachusetts, US |
| PGE2 | Double UCB; one with FT1050 treatment; the other is unmanipulated | Hematologic malignancies | NCT00890500 | Phase I; Completed | Massachusetts General Hospital, Boston, Massachusetts, US; Dana-Farber Cancer Institute, Boston, Massachusetts, US |
| PGE2 | Double UCB; one with FT1050 treatment; the other is unmanipulated | Hematologic malignancies | NCT01627314 | Phase II; Terminated (Business decision) | Multicenter in US |
| Fucosylation | Double UCB; one is fucosylated; the other is unmanipulated | Hematologic malignancies | NCT01471067 | Phase I; Completed | University of Texas MD Anderson Cancer Center, Houston, Texas, US |
| Hyperbaric Oxygen | Double UCB with administration of hyperbaric oxygen | Hematologic malignancies | NCT02099266 | NA; Completed | University of Kansas Medical Center, Kansas City, Kansas, US |
| IBMT | Intrabone infusion of double UCB | Hematological malignancies | NCT00886522 | Phase II; Completed | Hematology Institute “L. and A. Seràgnoli”, S. Orsola-Malpighi University Hospital, Bologna, Italy |
SR-1-mediated Expansion
SR-1 is a purine derivative identified by a high-throughput screen to promote human HSC expansion via inhibition of aryl hydrogen receptor (AhR) signaling. A clinical trial based on a double UCB platform with one SR-1-expanded and one unmanipulated UCB unit was recently completed (NCT01474681). In this trial, UCB CD34+ cells were isolated and cultured with SR-1, SCF, TPO, and FL for 15 days and then infused into recipients together with CD34− portion and an unmanipulated UCB unit. This strategy resulted in HSC expansion on a large scale, with an 854.0-fold increase in total nucleated cells and 330.0 in CD34+ cells. In all 17 patients, engraftment occurred, with a significant improvement in the median time to neutrophil (15 days) and platelet (49 days) recovery. In terms of GVHD, the rates of acute and chronic GVHD in SR-1 group were similar to historical cohorts.

UM171-mediated Expansion
UM171 is a pyrimidoindole derivative that promotes UCB long-term HSC expansion independent of AhR signaling. The presence of UM171 leads to inhibition of erythroid and megakaryocyte expression. Mechanistic studies demonstrate that UM171 effectively targets RCOR1, LSD1, and HDAC2 through CRL3/KBTBD4 complex by proteasomal degradation, which further re-establishes H3K4me2 and H3K27ac epigenetic marks to prevent HSC attrition during in vitro culture. It has also been reported that UM171 treatment selectively increases EPCR+ or ITGA3+ cell populations, which possess higher long-term repopulation ability than the EPCR− or ITGA3− component. In a recently completed trial, 22 patients who received a single 7-day UM171-expanded UCB unit experienced a marked shortening of the median time to neutrophil (18 days) and platelet (42 days) recovery. Notably, patients infused with UM171-expanded UCB also had less GVHD occurrence than those infused with double unmanipulated UCB units. In light of this observation, many more UM171-related trials have begun in multiple centers.

Mesenchymal Stromal Cell (MSC)-mediated Expansion
To mimic the BM niche that supports HSC self-renewal, researchers have cultured UCB CD34+ cells on STRO-3+ MSCs supplemented with SCF, TPO, FL, and G-CSF. In this clinical trial (NCT00498316), total nucleated cell and CD34+ cell numbers were increased 12.2- and 30.1-fold, respectively, at 14 days postculture. Participants received one cocultured and one unmanipulated UCB unit successively, and 23 of the 24 recipients showed mixed chimeras, with a markedly shortened median time to recovery of neutrophils (15 days) and platelets (42 days). The rate of acute GVHD was 55%, comparable to that of historical cohorts. However, unmanipulated UCB units prevailed in all patients' chimera at 1-year posttransplantation, suggesting that the engrafting ability was impaired in cocultured UCB units.

UCB Homing Promotion
Prostaglandin-mediated Homing
A long-activating derivative of prostaglandin E2, 16,16-dimethyl-PGE2 (dmPGE2), has been identified as increasing the long-term HSC number in zebrafish, mice, and humans via enhancement of Wnt signaling and promotion of survival; dmPGE2 also upregulates expression of
| Treatment                  | Agonist                                                                 | Culture period | Expansion fold | Cell dose (cells/kg recipient weight) | Hematopoietic engraftment (number of patients) | Day of engraftment | Possible mechanism                                                                 |
|---------------------------|--------------------------------------------------------------------------|----------------|----------------|--------------------------------------|------------------------------------------------|-------------------|-----------------------------------------------------------------------------------|
| Cytokines                 | SCF, G-CSF, MGDF                                                         | 10 d           | TNC: 56.0; CD34: 4.0 | TNC: 1.2 x 10^5; CD34: 7.4 x 10^4 | NA TNC: 1.0 x 10^4; CD34: 10.4 x 10^4 | 30/30 | Promotion of self-renewal and prevention of differentiation                        |
| Copper chelator           | TEPA, SCF, FL, IL-6, TPO                                                 | 21 d           | TNC: 219.0; CD34: 6.0 | TNC: 1.7 x 10^5; CD34: 5.5 x 10^4 | TNC: 4.4 x 10^6; CD34: 6.5 x 10^6 | NA 9/10 | Neutrophile 30 d; Platelets: 48 d                                                 |
| Copper chelator           | TEPA, SCF, FL, IL-6, TPO                                                 | 21 d           | TNC: 400.0; CD34: 77.0 | TNC: 2.4 x 10^5; CD34: 2.3 x 10^5 | TNC: 0.9 x 10^5; CD34: 9.4 x 10^5 | NA 8/5/10 | Neutrophile 21 d; Platelets: 54 d                                                 |
| BMT                       | NA                                                                       | NA             | NA             | NA TNC: 2.6 x 10^5; CD34: 1.0 x 10^5 | NA TNC: 2.6 x 10^5; CD34: 1.0 x 10^5 | 28/28 | Neutrophile 23 d; Platelets: 36 d                                                 |
| Notch ligand              | Delta1^{ex}, Fibronectin, SCF, TPO, FL, IL-3, IL-6                      | 16 d           | TNC: 562.0; CD34: 164.0 | TNC: 3.3 x 10^5; CD34: 2.4 x 10^5 | TNC: 4.6 x 10^5; CD34: 6.0 x 10^5 | NA 7/10 | Neutrophile 16 d; Platelets: NA                                                   |
| MSC coculture             | SCF, TPO, FL, G-CSF                                                     | 14 d           | TNC: 12.2; CD34: 30.1 | TNC: 2.3 x 10^5; CD34: 4.0 x 10^4 | TNC: 5.8 x 10^5; CD34: 1.0 x 10^5 | TNC: 8.3 x 10^5; CD34: 1.2 x 10^5 | 23/24 | Neutrophile 15 d; Platelets: 42 d                                                 |
| dmPGE2 priming            | dmPGE2                                                                  | 2 h            | NA             | TNC: 1.7 x 10^5; CD34: 6.0 x 10^4 | TNC: 1.8 x 10^5; CD34: 7.0 x 10^5 | NA 10/12 | Neutrophile 17.5 d; Platelets: 43 d                                              |
| C3a priming               | C3a                                                                      | 15 minutes     | NA             | TNC: 2.5 x 10^5; CD34: 3.4 x 10^5 | CD34: 3.2 x 10^5; CD34: 7.6 x 10^5 | NA 21/29 | Neutrophile 7 d; Platelets: NA                                                   |
| DPP4 inhibition           | Sitagliptin                                                              | NA             | NA             | TNC: 2.4 x 10^5; CD34: 1.0 x 10^5 | NA TNC: 2.4 x 10^5; CD34: 1.0 x 10^5 | 17/17 | Neutrophile 21 d; Platelets: 34 d                                                 |
| Nicotinamide              | Nicotinamide, SCF, TPO, IL-6, FBS                                       | 21 d           | TNC: 486.0; CD34: 72.0 | TNC: 2.6 x 10^5; CD34: 0.6 x 10^5 | TNC: 2.5 x 10^5; CD34: 3.5 x 10^5 | NA 34/36 | Neutrophile 11.5 d; Platelets: 34 d                                              |
| Nicotinamide              | Nicotinamide, SCF, TPO, IL-6, FBS                                       | 21 d           | TNC: NA; CD34: 33.0 | TNC: 4.9 x 10^5; CD34: 6.3 x 10^5 | NA TNC: 4.9 x 10^5; CD34: 6.3 x 10^5 | NA 10/11 | Neutrophile 13 d; Platelets: 33 d                                                 |
| Fucosylation              | Fucosyltransferase-VI, guanosine dihydrofucose fucose                    | 30 minutes     | NA             | TNC: 2.6 x 10^5; CD34: 1.2 x 10^5 | TNC: 1.8 x 10^5; CD34: 0.9 x 10^5 | TNC: 4.26 x 10^5; CD34: 2.4 x 10^5 | 20/22 | Neutrophile 17 d; Platelets: 35 d                                                 |
| SR-1                      | SR-1, SCF, TPO, FL, IL-6                                                | 15 d           | TNC:585.0; CD34: 330.0 | TNC: 2.0 x 10^5; CD34: 4.0 x 10^5 | TNC: 3.0 x 10^5; CD34: 1.75 x 10^5 | TNC: 7.0 x 10^5; CD34: 1.82 x 10^5 | 17/17 | Neutrophile 15 d; Platelets: 49 d                                                 |
| UM171                     | UM171, SCF, TPO, FL                                                     | 7 d            | TNC: NA; CD34: 35.4 | TNC: 2.92 x 10^5; CD34: 28.8 x 10^5 | NA TNC: 2.92 x 10^5; CD34: 28.8 x 10^5 | NA 22/22 | Neutrophile 18 d; Platelets: 42 d                                                 |
CXCR4, which is a homing receptor of HSCs to the BM niche. In a pilot study, 12 participants who received one dmPGE2-pulsed UCB unit and one unmanipulated UCB unit displayed promising improvement in hematopoietic engraftment, and the median time to neutrophil (17.5 days) and platelet (43 days) recovery was shortened. Interestingly, 10 of the 12 patients showed 100% engraftment with dmPGE2-pulsed UCB units, suggesting a functional boost of HSC engraftment ability with dmPGE2 treatment. In terms of GVHD, only 4 patients experienced mild GVHD symptom.

### C3a-mediated Homing

C3a is a component of the complement system. C3a can be produced by BM stromal cells. It was found that C3a is able to promote CD34+ cell migration toward SDF-1 via the surface C3a receptor in vitro, acting through the SDF-1-CXCR4 axis to facilitate HSC homing to BM. In one clinical trial, the UCB unit was primed with C3a for 15 minutes and then infused into participants along with one unmanipulated UCB unit. Strikingly, the median time to neutrophil recovery with C3a priming was 7 days. However, only 9 of the 29 patients showed engraftment skewing toward C3a-primed units, suggesting that C3a priming may act on short-term repopulating cells rather than long-term HSCs.

### DPP4-mediated Homing

Dipeptidyl peptidase-4 (DPP4) cleaves SDF-1 at the N-terminus to generate a truncated form that competitively blocks the binding of wild-type SDF-1 to CXCR4, thus impairing HSC homing. Sitagliptin is an oral drug that inhibits DPP4 activity and enhances HSC engraftment in mouse models. In a clinical trial, participants received 600 mg sitagliptin once a day before UCBT until 2 days afterward. However, the outcome was not exciting, with only modest improvement in the median time to neutrophil recovery (21 days). Anyway, the incidence of GVHD was rare in this trial, with only one patient experiencing grade II GVHD.

### Fucosylation-mediated Homing

Preclinical studies have shown that fucosylation of UCB cells can augment P-selectin and E-selectin binding of HSCs and thereby enhance homing to BM. In a clinical trial, UCB units were incubated with fucosyl-transferase VI in vitro for 30 minutes to allow fucosylation and then infused into patients together with unmanipulated UCB units. Twenty of 22 recipients showed engraftment, with a markedly shortened median time to neutrophil (27 days) and platelet (26 days) recovery. Besides, there was not increase in GVHD incidence in this trial.

### Intrabone Marrow Transplantation

It has been reported that only 10-15% of HSCs successfully home to the BM niche after intravenous infusion. Intra-BM transplantation in a mouse model showed 10-fold efficiency of intravenous transplantation in marrow repopulation. Based on these observations, a clinical trial was conducted to transplant a UCB unit intra-BM. All 28 patients exhibited mixed chimeras after UCBT, but modest improvement in the median time to neutrophil (23 days) and platelet (36 days) recovery occurred.
Hyperbaric Oxygen Therapy (HBT)

UCB CD34+ cells display an impaired ability to migrate to the BM niche after exposure to erythropoietin (EPO), but lowering the EPO concentration by HBT can facilitate UCB HSC homing to the BM niche in a mouse model. In a clinical trial, patients received HBT before single-unit UCBT, and the median time to neutrophil (15.0 days) and platelet (36.5 days) recovery was significantly improved. However, overall survival did not differ from that of conventionally treated patients.

Recent Progress in Preclinical Studies on UCB Engraftment

In a normal physiological environment, self-renewal of HSPCs is regulated by complex regulatory networks of intrinsic factors (such as transcription factors, cell cycle regulators, and various metabolic pathways) as well as external cues. Supportive cells in the BM niche can produce a variety of cell growth factors, such as SCF, TPO, TGF-β1, and G-CSF, and provide cell-cell contact signals to affect HSC behavior. In general, these extrinsic signals are transmitted by surface or intracellular receptors and adaptors and converge to a regulatory core comprising key transcription factors. The delicate balance between self-renewal and differentiation is determined by these core regulators. Numerious studies have sought to promote HSC self-renewal versus differentiation via certain stimuli. Recent progress in preclinical studies may help to improve UCB engraftment in the clinical setting (summarized in Table 3).

Epigenetic Modifiers

De novo transcription of genes is regulated by local chromatin accessibility through epigenetic modifications, which has been demonstrated to play a key role in cell fate determination in various cell types. A recent study reported that after 9 days of culture, the DNA methyltransferase inhibitors 5azaD and TSA increased the number of SCID-repopulating cells (SRC) among UCB CD34+ cells by 7.0-fold. Additionally, the mechanistic study found a marked decrease in methylation levels at an HSC self-renewal gene loci after 5azaD and TSA treatment. Surprisingly, another agent, the HDAC3 inhibitor VPA, led to SRC number maintenance but not increase, which seems contradictory to other reports. This result may have been caused by certain substances in serum that blocked the function of VPA, as serum-free culture of UCB CD34+ cells with VPA increased the SRC number by 36.0-fold after 7 days. Moreover, VPA was found to upregulate expression of the homing receptor CXCR4 and activity of ALDH in HSCs. In addition to HDAC3 inhibition, HDAC5 inhibition has been shown to improve UCB engraftment with the SRC number increasing 6.0-fold after 16 hours of treatment with the HDAC5 inhibitor LMK235, an effect that might be mediated by enhanced NF-κB activity and upregulated CXCR4 expression. Interestingly, a recent report demonstrated that UM171 was involved in epigenetic regulation of HSCs by targeting the components of CoREST complex (RCOR1, Lsd1, HDAC2) for degradation. In this study, the HDAC inhibitor panobinostat selectively expanded CD34+EPCR+HSCs after 4-day culture. Despite lacking of function assay, this study highlights the role of epigenetic regulation to orchestrate HSC activity. Other epigenetic modulators, such as histone acetyltransferase (HAT) and the bromodomain and extraterminal domain (BET) family, have also been reported to participate in HSC self-renewal. Garcinol, an inhibitor of HATs, caused a 2.5-fold increase in SRC number, and CPI-203, a BET inhibitor, enhanced UCB HSC engraftment by promoting megakaryocyte differentiation, possibly with an effect on megakaryocyte fate-promised HSCs which are at the top of the hematopoietic hierarchy. Overall, epigenetic modifiers play vital roles in HSC engrafting ability by selectively adjusting transcription factor activity on the self-renewal or differentiation network.

MAPK Superfamily

The mitogen-activated protein kinase (MAPK) superfamily is heavily involved in proliferation and various physiological processes, classified into the p38 MAPK, c-Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) signaling pathways. SB203580, a p38 inhibitor, led to modest enhancement in the case of UCB CD34+ cell engraftment. A more recent study screened out a structure-modified molecule named C7, causing a 2.0-fold increase in SRC number in UCB mononuclear cells. Furthermore, JNK has recently been proven to participate in HSC stemness and self-renewal regulation. The inhibition of JNK activity by JNK-IN-8 increases the SRC number among UCB CD34+ cells by 3.9 folds at 10 days post-culture. Moreover, a greater increase in SRC number was achieved by shortening the culture period to 24 hours and increasing the JNK-IN-8 concentration. Interestingly, the presence of a JNK inhibitor during HSC collection was also found to enhance long-term HSC recovery from UCB units. Mechanistically, JNK inhibition promotes self-renewal gene expression and prevents metabolic activation in HSCs.

Metabolic Regulation

It has been observed frequently that long-term HSCs are more metabolically inactive than are short-term HSCs. Low-level metabolic activity can reduce metabolite-related reactive oxygen species (ROS) accumulation and endoplasmic reticulum (ER) stress, thus maintaining HSC survival and stemness. In recent years, there have been various attempts to target metabolic regulation, including glycolysis and lipid metabolism. Resveratrol is a nonflavonoid polyphenol that activates SIRT1, which plays an essential antioxidative role. Activated SIRT1 in turn upregulates FOXO3a and then degrades cellular ROS. A recent study found that addition of resveratrol enhances serial engraftment of UCB CD34+ cells after 9 days of culture, with a comparable effect to SR-1. However, the specific number of SRCs was not calculated. Another study reported an important role for lipid metabolism in HSC self-renewal regulation. DEGS1 is a sphingolipid enzyme with low expression in long-term HSCs but high expression in differentiating progenitors. It was observed that DEGS1 expression in UCB CD34+ cells was rapidly upregulated upon culture in vitro, with the SRC number increasing by 2.5-fold in the presence of the DEGS1 inhibitor N-(4-hydroxyphenyl) retinamide (4HPR). Such enhancement of HSC engraftment may result from ER stress alleviation, autophagy promotion and ROS reduction. Notably, a greater increase in SRC number can be achieved by combining 4HPR with UM171 and SR-1. In the case of glycolysis modulation, the PPARγ inhibitor GW9662 achieved a 5.0-fold increase in SRC number by enhancing glycolysis and suppressing lipid metabolism.
Table 3. Recent progress in preclinical studies of UCB engraftment improvement

| Agents          | Input cells   | Culture media                                                                 | Culture period | Result                          | Possible mechanism                                                                 | Reference |
|-----------------|---------------|-------------------------------------------------------------------------------|----------------|---------------------------------|-----------------------------------------------------------------------------------|-----------|
| Small molecules |               |                                                                               |                |                                 |                                                                                   |           |
| 5azaD/TSA       | CD34⁺         | Serum-containing media, SCF, TPO, FL, IL-3                                     | 9 d            | 7.0-fold increase in SRCs       | Hypomethylation of HSC self-renewal genes                                         | 69        |
| VPA             | CD34⁺         | Serum-containing media, SCF, TPO, FL, IL-3                                     | 9 d            | Maintenance of SRCs             | Hypomethylation of HSC self-renewal genes                                         | 69        |
| VPA             | CD34⁺         | Serum-free media, SCF, TPO, FL, IL-3                                          | 7 d            | 36.0-fold increase in SRCs      | Uregulation of pluripotency genes and CXCR4, increased aldehyde dehydrogenase activity | 70        |
| LMK235          | CD34⁺         | RPMI, 10% FBS, SCF, TPO, FL                                                    | 16 h           | 6.0-fold increase in SRCs       | Inhibition of HDAC5, increased CXCR4 surface expression                            | 71        |
| Garcinol        | CD34⁺         | StemSpan SFEM, SCF, TPO, FL                                                    | 7 d            | 2.5-fold increase in SRCs       | Inhibition of HATs                                                                  | 72        |
| CIP203          | CD133⁺        | StemSpan SFEM, SCF, TPO, FL                                                    | 5 d            | Improved BM engraftment at 21 weeks post-transplantation | Inhibition of BET, promotion of megakaryocyte differentiation                      | 73        |
| SB203580        | CD133⁺        | StemSpan H3000, SCF, TPO, FL                                                   | 7 d            | Improved BM engraftment at 10 weeks post-transplantation | Inhibition of the p38/MAPK pathway, upregulation of CXCR4                        | 74        |
| C7              | MNC           | StemSpan SFEM, SCF, TPO, FL, IGFBP-2                                           | 11 d           | 2.5-fold increase in SRCs       | Inhibition of the p38/MAPK pathway                                                  | 75        |
| JNK-IN-8        | CD34⁺         | StemSpan SFEM, SCF, TPO, FL, IGFBP-2                                           | 10 d           | 3.9-fold increase in SRCs       | Inhibition of the JNK pathway                                                      | 76        |
| JNK-IN-8        | CD34⁺         | StemSpan SFEM, SCF, TPO, FL                                                    | 24 h           | 13.5-fold increase in SRCs      | Inhibition of the JNK pathway                                                      | 77        |
| Baclofen        | CD34⁺         | NA                                                                            | 2 h            | Improved BM engraftment at 16 weeks post-transplantation | Agonization of GABA signaling, promotion of B-cell differentiation                 | 78        |
| Resveratrol     | CD34⁺         | StemSpan SFEM, SCF, TPO, FL, IL-6                                              | 9 d            | Improved engraftment of primary and secondary transplants | Reduction of oxidative stress                                                      | 79        |
| 4HPR            | Lin MNC       | StemPro, SCF, TPO, FL, IL-3, IL-6, GM-CSF                                      | 8 d            | 2.5-fold increase in SRCs       | Inhibition of DEGS1, activation of ER stress and autophagy, reduction of ROS       | 80        |
| GW9662          | CD34⁺         | RPMI, 10% FBS, SCF, TPO, FL                                                   | 4 d            | 5.0-fold increase in SRCs       | Antagonization of PPAR-γ signaling, enhancement of glycolysis                     | 81        |
| Angiogenin      | CD34⁺         | StemSpan SFEM                                                                 | 2 h            | 8.9-fold increase in SRCs       | Promotion of tiRNA production and quiescence of HSPCs                             | 82        |
| NOVCCN3         | CD34⁺         | StemSpan SFEM, SCF, TPO, FL                                                    | 8 h            | 6-fold increase in SRCs         | Recruitment of otherwise nonfunctioning HSCs                                      | 83        |
| OAC1            | CD34⁺         | RPMI, 10% FBS, SCF, TPO, FL                                                    | 4 d            | 3.5-fold increase in SRCs       | Induction of OCT4 expression                                                      | 84        |
| Fed-batch system| Lin MNC       | IMDM, 20% BIT serum substitute, SCF, TPO, FL                                  | 12 d           | 11.0-fold increase in SRCs      | Global maintenance of subthreshold levels of inhibitory factors                    | 85        |
| Agents | Input cells | Culture media | Culture period | Result | Possible mechanism | Reference |
|--------|-------------|----------------|----------------|--------|--------------------|-----------|
| **Cellular niches** | | | | | | |
| Revitalized MSCs (transduced with Klf7, Ostf1,Xbp1, Irf3 and Irf7) | CD34<sup>+</sup> | StemSpan SFEM, 10% KSR, TPO | 6 d | 5.7-fold increase in SRCs | Reduced DNA damage | 86 |
| Extracellular matrices | | | | | | |
| Zwitterionic hydrogel | CD34<sup>+</sup> | StemSpan SFEM II, SCF, TPO, FL, IL-6, IL-3 | 24 d | 78.0-fold increase in SRCs | Reduced metabolic activity; avoidance of ROS production, p38α, mTORC and p16INK activation | 87 |
| 3D fibrin/collagen/PCL scaffolds with/without MSC | CD34<sup>+</sup> | StemSpan, SCE, TPO, FGF-1, ANGPTL-5, IGFBP-2 | 7 d | Improved BM engraftment at 12 weeks post-transplantation | Unclear | 88 |
| PES nanofiber | CD34<sup>+</sup> | StemSpan, SCE, TPO, FL, IL-3 | 10 d | Improved BM engraftment at 6 weeks post-transplantation | Unclear | 89 |
| **Combination** | | | | | | |
| LY2228820, rapamycin, SR-1 | CD34<sup>+</sup> | StemSpan SFEM, SCF, TPO, FL, IL-6 | 7 d | 4.1-fold increase in SRCs | Coinhibition of p38α, mTORC1 and AhR signaling, reduction of senescence | 90 |
| 4HPR, UM171, SR-1 | Lin-MNC | StemPro, SCE, TPO, FL, IL-3, IL-6, GM-CSF | 8 d | 4.8-fold increase in SRCs | Inhibition of DEGS1, AhR signaling and erythroid and megakaryocyte differentiation | 80 |
| MLLT3 overexpression, UM171, SR-1 | CD34<sup>+</sup> | StemSpan SFEM II, SCF, TPO, FL | 15 d | 12.5-fold increase in SRCs | Protection of HSC stemness program through DOT1L and H3K79me2 | 91 |

Abbreviations: 4HPR, N-(4-hydroxyphenyl) retinamide; 5azaD/TSA, 5aza-2′-deoxycytidine/trischostatin A; AhR, aryl hydrocarbon receptor; BET, bromodomain and extraterminal domain; CXCR4, CXC chemokine receptor 4; DEGS1, Delta 4-desaturase, sphingolipid 1; DOT1L, DOT1-like histone H3K79 methyltransferase; FBS, fetal bovine serum; FGF-1, fibroblast growing factor-1; FL, FMS-like tyrosine kinase 3 ligand; GABA, γ-aminobutyric acid; GM-CSF, granulocyte-macrophage colony-stimulating transcription factor 4; HAT, histone acetyltransferase; HDAC, histone deacetylase; IL, interleukin; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MLLT3, myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila) translocated to, 3; MNC, mononuclear cell; MSC, mesenchymal stromal cell; mTORC1, mammalian target of rapamycin complex 1; OCT4, octamer-binding transcription factor 4; PES, polyethersulfone; PPAR, peroxisome proliferator-activated receptor; ROS, reactive oxygen species; SCF, stem cell factor; SRC, SCID-repopulating cells; SR-1, stem-regentin 1; TPO, thrombopoietin; VPA, valproic acid.
These observations suggest that promoting quiescence is beneficial for HSC stemness preservation. Other agents, for instance, angiogenin, promote HSC quiescence by enhancing tRNA production in HSCs, and NOV/CCN3 is reported to increase the HSC number via cell cycle inhibition and metabolic suppression.

**Extracellular Matrix**

The ECM is an important component that provides signals to regulate HSC behavior. Indeed, the ECM has a significant effect on biological processes such as cell differentiation, proliferation, adhesion, morphogenesis, and phenotypic expression.  

BM-derived MSCs have been demonstrated to provide certain signals for HSCs to proliferate and self-renew in both clinical trials and preclinical studies. Nevertheless, MSCs are not easily produced on large scales, and there are difficulties in quality control. Therefore, a more defined culture method is needed to facilitate translation to the clinic. Many biomaterials have been tested for their ability to enhance HSC self-renewal, but most of them have failed. Even the most efficient methods, such as 3D fibrin/collagen/PCL scaffolds and PES nanofibers, led to only a modest increase in short-term engraftment. However, strikingly, a recent report indicated that zwitterionic hydrogel markedly increased the SRC number among UCB CD34+ cells by 78.0-fold after a 24-day 3D culture via multiple signaling pathways, including reduced metabolic activity and avoiding ROS production and p38, mTORC and p16INK activation. This study suggested that fine-tuned orchestration of diverse cues is important to achieve better regulation of the HSC core network.

**Discussion**

Clinical trials have demonstrated the promising translational potential of ex vivo manipulation of UCB to improve HSC engraftment. Regardless, more endeavors are needed to explore more efficient strategies, as many methods still rely on double UCB platforms, except for NiCord and UM171, the clinical benefit of which requires further evaluation. Despite many positive results using preclinical mouse models, there is low translational efficiency to human counterparts of many positive results using preclinical mouse models, there is low translational efficiency to human counterparts of

**Acknowledgments**

This study is supported by the National Natural Science Foundation of China (21991081) and Newish Technology (Beijing) Co., Ltd.

**Conflict of Interest**

The authors declared no potential conflicts of interest.

**Author Contributions**

H.X. and Z.S.: conception and design; X.S.: financial support; Z.S., H.X. and B.Y.: manuscript writing; X.S.: final approval of manuscript.

**Data Availability**

The data that support the findings of this study are available from the corresponding author upon reasonable request.

**References**

1. Orkin SH, Zon LI. Hematopoiesis: an evolving paradigm for stem cell biology. *Cell* 2008;132(4):631-644. https://doi.org/10.1016/j.cell.2008.01.025

2. Copeland EA. Hematopoietic stem-cell transplantation. *N Engl J Med*. 2006;354(17):1813-1826. https://doi.org/10.1056/NEJMra052638

3. Chabannon C, et al. Hematopoietic stem cell transplantation in its 60s: a platform for cellular therapies. *Sci Transl Med*. 2018;10(436). https://doi.org/10.1126/scitranslmed.aap9630

4. Gratwohl A, et al. One million haemopoietic stem-cell transplants: a retrospective observational study. *Lancet Haematol*. 2015;2(3):e91-100. https://doi.org/10.1016/S2352-3026(15)00028-9

5. Alousi A, et al. Peripheral blood versus bone marrow from unrelated donors: bone marrow allografts have improved long-term overall and graft-versus-host disease-free, relapse-free survival. *Biol Blood Marrow Transplant*. 2019;25(2):270-278. https://doi.org/10.1016/j.bbmt.2018.09.004

6. Panch SR, Szymanski J, Savani BN, Stroncek DF. Sources of hematopoietic stem and progenitor cells and methods to optimize yields for clinical cell therapy. *Biol Blood Marrow Transplant*. 2017;23(8):1241-1249. https://doi.org/10.1016/j.bbmt.2017.05.003

7. Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. *Blood* 2013;122(5):491-498. https://doi.org/10.1182/blood-2013-02-453175

8. Dessels C, Alessandrini M, Pepper MS. Factors influencing the umbilical cord blood stem cell industry: an evolving treatment landscape. *Stem Cells Transl Med*. 2018;7(9):643-650. https://doi.org/10.1002/sctm.17-0244

9. Smith AR, Wagner JE. Alternative hematopoietic stem cell sources for transplantation: place of umbilical cord blood. *Br J Haematol*. 2009;147(2):246-261. https://doi.org/10.1111/j.1365-2141.2009.07828.x

10. Bart T. Cost effectiveness of cord blood versus bone marrow and peripheral blood stem cells. *ClinicoEcon Outcomes Res*. 2010;2:141-147. https://doi.org/10.2147/ceor.s11210

11. Majhail NS, et al. Costs of pediatric allogeneic hematopoietic cell transplantation. *Pediatr Blood Cancer* 2010;54(1):138-143. https://doi.org/10.1002/pbc.22250

12. Bari S, et al. Expansion and homing of umbilical cord blood hematopoietic stem and progenitor cells for clinical transplantation. *Biol Blood Marrow Transplant*. 2015;21(6):1008-1019. https://doi.org/10.1016/j.bbmt.2014.12.022

13. Bello AB, Park H, Lee SH. Current approaches in biomaterial-based hematopoietic stem cell niches. *Acta Biomater*. 2018;72:1-15. https://doi.org/10.1016/j.actbio.2018.03.028

14. Lund TC, Boitano AE, Delaney CS, Shpall EJ, Wagner JE. Advances in umbilical cord blood manipulation—from niche to bedside. *Nat Rev Clin Oncol*. 2015;12(3):163-174. https://doi.org/10.1038/nrcli.2014.215

15. Pinho S, Frenette PS. Haematopoietic stem cell activity and interactions with the niche. *Nat Rev Mol Cell Biol*. 2019;20(5):303-320. https://doi.org/10.1038/s41580-019-0103-9

16. Crane GM, Jeffery E, Morrison SJ. Adult haematopoietic stem cell niches. *Nat Rev Immunol*. 2017;17(9):573-590. https://doi.org/10.1038/nri.2017.53
35. Popat U, et al. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood 2015;125(19):2885-2892. https://doi.org/10.1182/blood-2015-01-607366
36. Wagner JE Jr, et al. Phase I/II trial of StemRegenin-1 expanded umbilical cord blood hematopoietic stem cells supports testing as a stand-alone graft. Cell Stem Cell 2016;18(1):144-155. https://doi.org/10.1016/j.stem.2015.10.004
37. Cohen S, et al. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study. Lancet Haematol. 2020;7(2):e134-e145. https://doi.org/10.1016/S2353-3326(19)30202-9
38. Mina A, et al. Long-term results of a pilot study evaluating hyperbaric oxygen therapy to improve umbilical cord blood engraftment. Ann Hematol. 2019;98(2):481-489. https://doi.org/10.1007/s00277-018-3532-1
39. Kumar S, Geiger H. HSC niche biology and HSC expansion ex vivo. Trends Mol Med. 2017;23(9):799-819. https://doi.org/10.1016/j.tmm.2017.07.003
40. Walasek MA, van Os R, de Haan G. Hematopoietic stem cell expansion: challenges and opportunities. Ann N Y Acad Sci. 2012;1266(1):138-150. https://doi.org/10.1111/j.1749-6632.2012.06549.x
41. Kollet O, et al. The soluble interleukin-6 (IL-6) receptor/IL-6 fusion protein enhances in vitro maintenance and proliferation of human CD34+CD38−/low cells capable of repopulating severe combined immunodeficiency mice. Blood 1999;94(6):923-931. https://doi.org/10.1182/blood.V94.6.923-931.931
42. Piaccibello W, et al. Engraftment in nonobese diabetic severe combined immunodeficient mice of human CD34+ cord blood cells after ex vivo expansion: evidence for the amplification and self-renewal of repopulating stem cells. Blood 1999;93(11):3736-3749. https://doi.org/10.1182/blood.V93.11.3736
43. Ueda T, et al. Expansion of human NOD/SCID-repopulating cells by stem cell factor, Flk2/Flt3 ligand, thrombopoietin, IL-6, and soluble IL-6 receptor. J Clin Invest. 2000;105(7):1013-1021. https://doi.org/10.1172/JCI8583
44. Rossmanith T, et al. Interleukin 3 improves the ex vivo expansion of primitive human cord blood progenitor cells and maintains the engraftment potential of scid repopulating cells. Stem Cells. 2001;19(4):313-320. https://doi.org/10.1634/stemcells.19-4-313.931
45. Peled T, et al. Linear polyamine copper chelator tetaethylenepentamine augments long-term ex vivo expansion of cord blood-derived CD34+ cells and increases their engraftment potential in NOD/SCID mice. Exp Hematol. 2004;32(6):547-555. https://doi.org/10.1016/j.exphem.2004.03.002
46. Delaney C, Varnum-Finney B, Aoyama K, Brashem-Stein C, Bernstein ID. Dose-dependent effects of the Notch ligand Delta1 on ex vivo differentiation and in vivo marrow repopulating ability of cord blood cells. Blood 2005;106(8):2693-2699. https://doi.org/10.1182/blood.V106.8.2693-2699.931
47. Dahlberg A, et al. Notch-mediated expansion of cord blood progenitors: maintenance of transcriptional and epigenetic fidelity. Leukemia 2015;29(9):1948-1951. https://doi.org/10.1038/leu.2015.61
48. Denu JM. Vitamin B3 and sirtuin function. Trends Biochem Sci. 2003;30(9):479-483. https://doi.org/10.1016/j.tibs.2005.07.004
49. Geisler C, et al. Nicotinamide, a SIRT1 inhibitor, inhibits differentiation and facilitates expansion of hematopoietic progenitor cells with enhanced bone marrow homing and engraftment. Exp Hematol. 2012;40(4):342-355.e341. https://doi.org/10.1016/j.exphem.2011.12.005
50. Boitano AE, et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 2010;329(5997):1345-1348. https://doi.org/10.1126/science.1191536
51. Fares I, et al. Cord blood expansion. Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal. Science 2014;345(6203):1509-1512. https://doi.org/10.1126/scienc.1256337
52. Charagouli, J. et al. UM171 preserves epigenetic marks that are reduced in ex vivo culture of human HSCs via potentiation of the
53. Fares I, et al. EPIC expression marks UM171-expanded CD34+ cord blood stem cells. Blood 2017;129(25):3344-3351. https://doi.org/10.1182/blood-2016-11-750729

54. Tomellini, E. et al. Integrin-α3 is a functional marker of ex vivo expanded human long-term hematopoietic stem cells. Cell Rep. 2019;28(4):1063-73.e1065. https://doi.org/10.1016/j.celrep.2019.06.084.

55. Goessling, W. et al. Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models. Cell Stem Cell 2011;8(4):445-58. https://doi.org/10.1016/j.stem.2011.02.003.

56. Li L, et al. Prostaglandin E2 promotes survival of naive UCB T cells via the Wnt/beta-catenin pathway and alters immune reconstitution after UCBT. Blood Cancer J. 2014;4:e178. https://doi.org/10.1038/bcj.2013.75.

57. North TE, et al. Prostaglandin E2 regulates vertebrate haematopoietic stem progenitor cells by automated control of inhibitory feedback signaling. Science 2009;323(5915):1007-1011. https://doi.org/10.1126/science.1160626.

58. Hoggatt J, Singh P, Sampath J, Pelus LM. Prostaglandin E2 enhances hematopoietic stem cell homing and engraftment by CD26. Leukemia 2002;16(12):2100-1. https://doi.org/10.1038/sj.leu.2402986.

59. Fares I, et al. EPCR expression marks UM171-expanded CD34(+) hematopoietic stem cells. Cell Stem Cell 2011;5(2):127-35. https://doi.org/10.1016/j.stem.2010.08.007.

60. Chaurasia P, Gajzer DC, Schaniel C, D’Souza S, Hoffman R. Epigenetic reprogramming induces the expansion of cord blood stem cells. J Clin Invest. 2014;124(6):2378-2395. https://doi.org/10.1172/jci70313.

61. Christopherson KW 2nd, Hangoc G, Mantel CR, Broxmeyer HE. Modulation of hematopoietic stem cell homing and engraftment by dichotomously regulating quiescence of stem and progenitor cells. Stem Cell Transl Med 2015;4(9):1064-1072. https://doi.org/10.5966/sctm.2014-0284.

62. Xia L, et al. Targeting JNK pathway promotes human hematopoietic stem cell expansion. Cell Discovery. 2019;5(1):1. https://doi.org/10.1038/s41421-018-0072-8.

63. Robinson SN, et al. Ex vivo fucosylation improves human hematopoietic stem cell quiescence and engraftment. Stem Cells Transl Med. 2022;11(6):597-603. https://doi.org/10.1038/s41377-022-01443-x.

64. Zhang L, et al. Engineering a haematopoietic stem cell niche by revitalizing mesenchymal stromal cells. Nat Cell Biol. 2019;21(5):560-567. https://doi.org/10.1038/s41556-019-0308-3.
87. Bai T, et al. Expansion of primitive human hematopoietic stem cells by culture in a zwitterionic hydrogel. Nat Med. 2019;25(10):1566-1575. https://doi.org/10.1038/s41591-019-0601-5
88. Ferreira MS, et al. Cord blood-hematopoietic stem cell expansion in 3D fibrin scaffolds with stromal support. Biomaterials. 2012;33(29):6987-6997. https://doi.org/10.1016/j.biomaterials.2012.06.029
89. Chua KN, et al. Functional nanofiber scaffolds with different spacers modulate adhesion and expansion of cryopreserved umbilical cord blood hematopoietic stem/progenitor cells. Exp Hematol. 2007;35(5):771-781. https://doi.org/10.1016/j.exphem.2007.02.002
90. Li X, et al. Coinhibition of activated p38 MAPKalpha and mTORC1 potentiates stemness maintenance of HSCs from SR1-expanded human cord blood CD34(+) cells via inhibition of senescence. Stem Cells Transl Med. 2020;9(12):1604-1616. https://doi.org/10.1002/sctm.20-0129
91. Calvanese V, et al. MLLT3 governs human haematopoietic stem-cell self-renewal and engraftment. Nature 2019;576(7786):281-286. https://doi.org/10.1038/s41586-019-1790-z
92. Lunyak VV, Rosenfeld MG. Epigenetic regulation of stem cell fate. Hum Mol Genet. 2008;17(R1):R28-R36. https://doi.org/10.1093/hmg/ddn149
93. Rodrigues CP, Shvedunova M, Akhtar A. Epigenetic regulators as the gatekeepers of hematopoiesis. Trends Genet. 2020;37(2):125-142. https://doi.org/10.1016/j.tig.2020.09.015
94. Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 2002;12(1):9-18. https://doi.org/10.1038/sj.cr.7290105
95. Wilson A, et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell 2008;135(6):1118-1129. https://doi.org/10.1016/j.cell.2008.10.048
96. Takizawa H, Regoes RR, Boddupalli CS, Bonhoeffer S, Manz MG. Dynamic variation in cycling of hematopoietic stem cells in steady state and inflammation. J Exp Med. 2011;208(2):273-284. https://doi.org/10.1084/jem.20101643
97. Qiu J, Papatsenko D, Niu X, Schaniel C, Moore K. Divisional history and hematopoietic stem cell function during homeostasis. Stem Cell Rep. 2014;2(4):473-490. https://doi.org/10.1016/j.stemcr.2014.01.016
98. Ito K, Bonora M, Ito K. Metabolism as master of hematopoietic stem cell fate. Int J Hematol. 2019;109(1):18-27. https://doi.org/10.1007/s12185-018-2534-z
99. Nakamura-Ishizu A, Ito K, Suda T. Hematopoietic stem cell metabolism during development and aging. Dev Cell. 2020;54(2):239-255. https://doi.org/10.1016/j.devcel.2020.06.029
100. Yun JM, Chien A, Jialal I, Devaraj S. Resveratrol up-regulates SIRT1 and inhibits cellular oxidative stress in the diabetic milieu: mechanistic insights. J Nutr Biochem. 2012;23(7):699-705. https://doi.org/10.1016/j.jnutbio.2011.03.012
101. Robinson SN, et al. Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant. 2006;37(4):359-366. https://doi.org/10.1038/sj.bmt.1705258
102. Wang L, et al. Generation of hematopoietic repopulating cells from human embryonic stem cells independent of ectopic HOXB4 expression. J Exp Med. 2005;201(10):1603-1614. https://doi.org/10.1084/jem.20041888
103. Oh IH, Lau A, Eaves CJ. During ontogeny primitive (CD34(+) CD38(-)) hematopoietic cells show altered expression of a subset of genes associated with early cytokine and differentiation responses of their adult counterparts. Blood 2000;96(13):4160-4168.
104. Graf L, Heimfeld S, Torok-Storb B. Comparison of gene expression in CD34+ cells from bone marrow and G-CSF-mobilized peripheral blood by high-density oligonucleotide array analysis. Biol Blood Marrow Transplant. 2001;7(9):486-494. https://doi.org/10.1053/bbmt.2001.v7.pm11669215
105. Kaufmann KB, et al. A latent subset of human hematopoietic stem cells resists regenerative stress to preserve stemness. Nat Immunol. 2021;22(6):723-734. https://doi.org/10.1038/s41590-021-00925-1